Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

UroSens Receives Funding and Enters into Clinical Trials

Published: Tuesday, June 18, 2013
Last Updated: Tuesday, June 18, 2013
Bookmark and Share
Board of directors strengthened with key appointments.

UroSens Ltd has announced that it has received £0.5M ($0.8M) investment and has entered into clinical trials to assess the accuracy of its novel UroSens Mcm5-ELISA diagnostic test for the detection of bladder cancer.

The funding has been received from Esperante, a Netherlands-based specialist life sciences venture investment firm, Northstar Ventures’ Finance for Business North East Accelerator Fund, and existing investors.

In addition to the £0.5M investment, UroSens has recently been awarded a grant of £250,000 from the Technology Strategy Board.

The new funding will be used to enable UroSens to carry out a series of clinical studies, which will see the Company working with over 1,200 patients at four leading UK hospitals.

The study is expected to be completed by October 2013. UroSens has secured ethics approval to conduct similar trials for the detection of prostate cancer.

With over 40,000 new cases of prostate cancer and 11,000 of bladder cancer each year in the UK, current diagnostic tests are unreliable, resulting in many unnecessary biopsies.

For both diseases, the UroSens Mcm5-ELISA diagnostic test is expected to significantly reduce the number of patients undergoing these invasive and costly procedures because it offers significantly more accurate diagnostic results.

The new test is based on intellectual property licensed exclusively from Cancer Research Technology (CRT), the technology transfer arm of Cancer Research UK.

The UroSens Mcm5-ELISA test is compatible with established assay technologies and automated platforms and has achieved CE mark as a research use only product, which will allow the product to be commercialized throughout the EU and certain wider markets.

UroSens has also announced two appointments to strengthen its board of directors. Joining the board, effective immediately, are Mr Dean Slagel of Esperante and Dr Alex Buchan of Northstar Ventures.

Dean Slagel has been appointed Non-Executive Director and brings over 20 years of life science industry operational, business development and investing experience.

Alex Buchan has been appointed Board Observer. He joined Northstar in September 2004 following a series of senior commercial roles in the biotechnology sector at companies including Cybersense, Compugen, SDI Europe, EnSys Europe and Archaeus.

Dr Ian Campbell, CEO at UroSens, said: “These are significant steps forward for our company. We are grateful to our existing shareholders, Northstar Ventures and Esperante for the investment. Alongside our successful TSB grant application, this new funding enables us to progress with clinical trials and increase the pace of our commercial development.”

Dr Alex Buchan of Northstar Ventures added: “Bladder cancer is the fifth most common cancer in the UK, with the highest recurrence rate of any malignancy. We are delighted to have invested in UroSens, with its pioneering detection tests and technology, and I look forward to working with the UroSens team.”

Dean Slagel of Esperante commented: “Esperante is delighted to have invested in UroSens, which offers a novel and potentially ground-breaking urological cancer diagnostic being developed under the leadership of an experienced and high calibre management team. We look forward to continuing to support UroSens through to commercialization.”

The Finance for Business North East Accelerator Fund is backed by the European Regional Development Fund and the European Investment Bank.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

UroSens Announces Name Change to Arquer Diagnostics Ltd
Rebranding reflects the company's decision to expand into new oncology areas.
Tuesday, July 21, 2015
UroSens Receives £2 Million Investment
Investment will lead to commercialisation of a urine-based diagnostic test for bladder and prostate cancer.
Monday, January 12, 2015
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
CDC Updates Zika Recommendations
CDC has issued updated Zika recommendations and guidance for healthcare providers with a focus on sexual transmission.
Review of the Analysis of Haemoglobin A1c for Diabetes Diagnostics
This paper aims to clarify methods, units, quality requirements, reference and cutoff limits for hemoglobin A1c (HbA1c) and ratio of blood glucose/HbA1c on the basis of the results from Finnish quality control surveys by comparing them to the literature.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
72% Rise in Metastatic Prostate Cancer
Over the 2003-2013 period metastatic cancer has increased by an average of 72%, this could be caused by lax screening, more aggressive disease or both.
Lab-Tested Diagnosis Needed When Treating Persistent Diarrhea
New PCR multiplex method makes lab testing more effective.
Biomarker for Multiple Sclerosis Detection Discovered
Winthrop-University Hospital researchers discover biomarker for multiple sclerosis detection.
Scientists Link Bipolar Disorder to Unexpected Brain Region
Researchers from The Scripps Research Institute have found that gene within the brain’s striatum could be linked to biopolar disorder.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!